ImmusanT Overview
- Year Founded
-
2010
- Status
-
Out of Business
- Employees
-
15
- Latest Deal Type
-
Out of Business
ImmusanT General Information
Description
Developer of therapeutic vaccines intended to treat people with autoimmune diseases. The company's platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes, thereby enabling clinicians to improve diagnosis and medical management of autoimmune diseases.
Contact Information
Website
www.immusant.comCorporate Office
- One Kendall Square
- Building 700
- Cambridge, MA 02139
- United States
Corporate Office
- One Kendall Square
- Building 700
- Cambridge, MA 02139
- United States
ImmusanT Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Out of Business | 08-Jan-2021 | Completed | Out of Business | |||
| 4. Later Stage VC (Series C) | 11-Sep-2018 | Completed | Clinical Trials - Phase 2 | |||
| 3. Later Stage VC (Series C) | 14-Nov-2017 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series B) | 30-Dec-2014 | $12.8M | $12.8M | Completed | Clinical Trials - Phase 1 | |
| 1. Early Stage VC (Series A) | 13-Dec-2011 | Completed | Startup |
ImmusanT Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 108,698,304 | $0.000100 | 8% | $0.23 | $0.23 | 1x | $0.23 | 28.87% |
ImmusanT Comparisons
Industry
Financing
Details
ImmusanT Competitors (65)
One of ImmusanT’s 65 competitors is Inovio Pharmaceuticals, a Corporation company based in Plymouth Meeting, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Cognition Therapeutics | Formerly VC-backed | New York, NY | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Apeptico | Formerly VC-backed | Vienna, Austria | ||||
| Iovance Biotherapeutics | Corporation | San Carlos, CA |
ImmusanT Patents
ImmusanT Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2020198434-A1 | Use of il-2 for diagnosis of celiac disease | Inactive | 26-Mar-2019 | ||
| WO-2019113037-A1 | Measurement of ccl20 after gluten exposure | Inactive | 04-Dec-2017 | ||
| AU-2018357840-A1 | Dosing regimens for celiac disease | Inactive | 30-Oct-2017 | ||
| CA-3080716-A1 | Dosing regimens for celiac disease | Inactive | 30-Oct-2017 | ||
| EP-3703728-A1 | Dosing regimens for celiac disease | Inactive | 30-Oct-2017 | A61K38/10 |
ImmusanT Signals
ImmusanT Acquisitions (1)
ImmusanT’s most recent deal was a Merger/Acquisition with Nexpep (Discovery Platform). The deal was made on 15-Mar-2011.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Nexpep (Discovery Platform) | 15-Mar-2011 | Merger/Acquisition | Drug Discovery |
ImmusanT FAQs
-
When was ImmusanT founded?
ImmusanT was founded in 2010.
-
Where is ImmusanT headquartered?
ImmusanT is headquartered in Cambridge, MA.
-
What is the size of ImmusanT?
ImmusanT has 15 total employees.
-
What industry is ImmusanT in?
ImmusanT’s primary industry is Drug Discovery.
-
Is ImmusanT a private or public company?
ImmusanT is a Private company.
-
What is ImmusanT’s current revenue?
The current revenue for ImmusanT is .
-
How much funding has ImmusanT raised over time?
ImmusanT has raised $52.8M.
-
Who are ImmusanT’s competitors?
Inovio Pharmaceuticals, Cognition Therapeutics, Sorrento Therapeutics, Apeptico, and Iovance Biotherapeutics are some of the 65 competitors of ImmusanT.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process